← board
TLX
distress 0/10 · well-funded / low risk$10.47+1%today-37% from 52w high
Revenue
$804M
Liquidity
$146M
Runway
—
Shares 1y
0%
Price & events
+37.4% over 6M
CatalystRating changeDilutionFinancingdashed = today
+1.5%
1D
-3.3%
1W
+2.5%
1M
+2.7%
3M
+37.6%
6M
-28.2%
1Y
—
2Y
—
5Y
-30.9%
All
Overview
- Market Cap
- $3.55B
- Enterprise Value
- $3.80B
- Volume
- 22.12K
- 52 Week Range
- $6.41 – $16.50
- Total Shares
- 338.78M
- Float Shares
- 272.81M
- Short %
- 0.05%
- % Held by Insiders
- 0.00%
- % Held by Institutions
- 0.85%
- RVOL
- 0.12x
- Beta
- 0.63
Pipeline · 0 trials · 0 upcoming
| Readout | Phase | Drug | Indication | Enroll | Status |
|---|---|---|---|---|---|
| No pipeline trials tracked. | |||||
Catalyst news & presentations · 0
- No catalyst news yet.
Approved drugs (0)
- none — clinical-stage
Capital structure — dilution & financing
Shares out: 338,777,049 · 0 offerings/1y · 0 PIPEs
- 2024-11-12EFFECTshelf_effective
🔒 Top holders — Pro
Institutional ownership + quarter-over-quarter accumulation/trimming.
Upgrade to ProWall St ratings
strong buy · target $21 (+101% upside) · 4 analysts
- 2026-07-07HC Wainwright & Co.Buy
- 2026-07-07CitigroupBuy
- 2026-07-06WedbushOutperform
- 2026-04-13WedbushOutperform
- 2026-04-13HC Wainwright & Co.Buy
- 2026-04-07HC Wainwright & Co.Buy
Competitors
- none identified
Recent news
- none
Not financial advice. Data: ClinicalTrials.gov, SEC EDGAR, FINRA, Nasdaq, Yahoo.